Leptin Plus Liraglutide Normalized Blood Sugar in Diabetic Mice Without Insulin

Researchers induced insulin-dependent diabetes in male mice using high-dose streptozotocin (which destroys insulin-producing beta cells). Diabetic mice were divided into four groups: leptin alone, liraglutide alone, leptin plus liraglutide, and untreated. A fifth group of healthy mice served as controls. Blood glucose was measured and glucose tolerance tests were performed to compare all five groups.

Type 1 diabetes currently requires lifelong insulin injections. If a combination of leptin and a GLP-1 agonist could partially or fully replace insulin in some patients, it could fundamentally change treatment options. This animal study provides early proof-of-concept that two non-insulin peptide hormones working together can achieve what neither does alone — complete glucose normalization in insulin-dependent diabetes.

GLP-1 agonists like liraglutide are already blockbuster drugs for type 2 diabetes and obesity, but their role in type 1 diabetes is mostly unexplored. Leptin has been studied in lipodystrophy and as an insulin adjunct. This study's finding that combining these two peptides can fully normalize glucose without insulin adds to growing interest in multi-hormone approaches to diabetes that go beyond insulin monotherapy.

This is a mouse study using chemically induced diabetes, which doesn't perfectly replicate human type 1 diabetes (an autoimmune disease). The abstract doesn't report specific glucose numbers, sample sizes per group, or statistical comparisons between the combination and monotherapy groups. Streptozotocin-induced diabetes destroys beta cells but lacks the autoimmune component. Long-term safety and durability of the effect were not assessed.